B-
BiotechTV - News
From Montreal: Congruence Therapeutics uses computational discovery to develop novel small molecule correctors and allosteric modulators - its lead program is for a high profile genetic obesity target
0:00-9:43
Founder & CEO Clarissa Desjardins describes Congruence's Revenir product engine and walks us through programs that include MC4R deficient obesity, which is in the clinic, alpha-1 antitrypsin deficienty, and Parkinson's.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/From-Montreal-Congruence-Therapeutics-uses-computational-discovery-to-develop-novel-small-molecule-correctors-and-allosteric-modulators---its-lead-program-is-for-a-high-profile-genetic-obesity-target-e3rsoke
Published
November 6, 2026
Duration
10 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
B-
BiotechTV - News
@biotechtvnews
#congruencetherapeuticsuses #developnovelsmall #highprofilegenetic #lifesciences
